Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | PTPRC | P08575 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | VSIR | Q9H7M9 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15876083 | 0.85 | MTNR1A (0.43) | KMT2AHTTPTPRCMEN1VSIR | |
| SCHEMBL38651523 | 0.85 | TSHR (0.53) | KDM4EPTPRCTSHRVSIR | |
| Hydrochloric Acid SCHEMBL8303604 | 0.83 | HPGD (0.49) | HPGDALDH1A1CHRM2KMT2AHTT | |
| SCHEMBL6432866 | 0.82 | ITGA4 (0.54) | HPGDALDH1A1CHRM2KMT2AKDM4E | |
| SCHEMBL5780166 | 0.82 | HIF1A (0.43) | ALDH1A1KMT2AHTTGAAPTPRC | |
| SCHEMBL734928 | 0.80 | ATM (0.55) | ALDH1A1KMT2AGAAKDM4EPTPRC | |
| SCHEMBL12318344 | 0.79 | MTNR1A (0.48) | HPGDALDH1A1KMT2ALMNAMEN1 | |
| SCHEMBL4707006 | 0.78 | CHRM2 (0.49) | HPGDALDH1A1CHRM2KMT2AHTT | |
| Hydrochloric Acid SCHEMBL6433307 | 0.78 | ATM (0.53) | ALDH1A1KMT2AGAAKDM4EPTPRC | |
| SCHEMBL3124959 | 0.78 | ALDH1A1 (0.55) | HPGDALDH1A1KMT2AHTTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050026836-A1 | Composition for the treatment of damaged tissue | DACK KEVIN NEIL (GB) | 2005-02-03 | — | — | US | disclosed |
| EP-1044967-B1 | 2-Pyridinylguanidine urokinase inhibitors | PFIZER (US) | 2004-08-11 | — | — | EP | disclosed |
| US-6673789-B2 | TREATING INFILTRATION OF IMMUNE CELLS INTO INFLAMMATORY SITES | PFIZER, INC. | 2004-01-06 | — | — | US | disclosed |
| US-20030203914-A1 | 2-Pyridinylguanidine urokinase inhibitors | DICKINSON ROGER PETER (GB) | 2003-10-30 | — | — | US | disclosed |
| US-20030199440-A1 | Composition for the treatment of damaged tissue | PFIZER INC. | 2003-10-23 | — | — | US | disclosed |
| US-6583162-B1 | 2-pyridinylguanidine urokinase inhibitors | WARNER-LAMBERT COMPANY | 2003-06-24 | — | — | US | disclosed |
| EP-1077945-B1 | ISOQUINOLINES AS UROKINASE INHIBITORS | PFIZER (US) | 2003-01-08 | — | — | EP | disclosed |
| EP-1242120-A2 | COMBINATIONS OF GROWTH FACTORS AND I:UPA OR I:MMP FOR THE TREATMENT OF DAMAGED TISSUE | Pfizer Limited (GB) | 2002-09-25 | — | — | EP | disclosed |
| CN-1318059-A | Isoquinolines as urokinase inhibitors | PFIZER (US) | 2001-10-17 | — | — | CN | disclosed |
| WO-2001049309-A2 | COMBINATIONS OF GROWTH FACTORS AND I: UPA OR I: MMP FOR THE TREATMENT OF DAMAGED TISSUE | PFIZER LIMITED (GB) | 2001-07-12 | — | — | WO | disclosed |
| EP-1077945-A1 | ISOQUINOLINES AS UROKINASE INHIBITORS | PFIZER INC. (US) | 2001-02-28 | — | — | EP | disclosed |
| EP-1044967-A2 | 2-Pyridinylguanidine urokinase inhibitors | PFIZER INC. (US) | 2000-10-18 | — | — | EP | disclosed |
| US-6093731-A | Isoquinolines | PFIZER INC. | 2000-07-25 | — | — | US | disclosed |
| WO-2000005214-A2 | ISOQUINOLINES AS UROKINASE INHIBITORS | PFIZER INC. (US) | 2000-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199440-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | HPGD 913/4885ALDH1A1 2641/4885CHRM2 4691/4885 |
| US-20050026836-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | HPGD 913/4885ALDH1A1 2641/4885CHRM2 4691/4885 |
| US-20030203914-A1 | 2-Pyridinylguanidine urokinase inhibitors | PLAU, SERPINE1, REN | HPGD 624/4885ALDH1A1 587/4885CHRM2 2068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.